Poolbeg Pharma PLC

Poolbeg Pharma PLC, a clinical-stage biopharmaceutical company develops immunotherapy for cancer in the United Kingdom. The company develops POLB 001, which is completed phase 1 clinical study for cancer immunotherapy-induced cytokine release syndrome; and phase 2 for the treatment of influenza. It also developing oral encapsulated GLP-1R agonist for obesity and diabetes treatment

AI program, a novel drug discovery therapies for the treatment of influenza and respiratory syncytial viruses. Incorporated in 2021, Poolbeg Pharma is headquartered in London, the United Kingdom.